• (919) 280-4806
  • info@healthscapedata.com

Your Go-To Source for Healthcare Information

Data Solution and Business Model

Outcomes: Improved research results, quality of care delivery, rationalized healthcare policy
The Database: licensed, aggregated, de-identified clinical patient data, analytics agnostic, regularly updated
The Data*: robust, patient level, real-time, continuous, longitudinal
Data Sources: Health Information Exchanges (HIEs), Healthcare Organizations & Systems, and Commercial data sources (five-year auto-renewable contracts)
Our Process: Projects are initiated by a Statement of Work (SOW) that specifies the volume of data, data field names, patient characteristics, timeline, number of data queries, data output format, transmission mode, problem statement, insights report structure, and fees.
Analysis Options*: Completed by Client, Third-party Partner, HealthScape Data LLC
Project Timeframes: Several hours to a few days
Cost: Dependent upon data volume and complexity of analysis required, ranging from $75,000 to over $500,000 for complex projects
Revenue Model: Revenue is shared with data partners (five-year auto-renewable contracts)

*A segment of the complete dataset is not available as real-time, continuous, longitudinal. If a third-party is chosen to conduct the analysis, it must also complete a SOW. The SOW limits the client or partner from attempting re-identification or reuse of the data beyond the stated purpose and time period.

Select Research Engagements

Medium-Sized Biopharmaceutical firm focused on the prevention of infectious and inflammatory conditions.

Study objectives were to provide descriptive statistics under several parameters:

  • Incidence of complications from venous or arterial catheters by…
  • Diagnosis code
  • Geography
  • Relationship of condition and comorbidity for each complication category and associated details
  • Data were presented on incidence for ICD-10 codes by:
  • Age
  • Gender
  • Site of diagnosis
  • Associations were found between select diagnoses and co-morbidities, positioning the Company well for prescribing appropriate use of its products

Specialty Pharmaceutical firm study designed to better understand opioid-induced nausea and prescription of antiemetics.

Study objectives were to provide detailed descriptive statistics under several parameters:

  • Migraine Patients vs. All Pain Patients
  • All patients with primary or secondary diagnosis of migraine headache or other conditions where pain is present AND
  • Prescribed a migraine medication (by brand) AND
  • Prescribed an antiemetic (by brand), segmented by:
  • Age
  • Gender
  • Diagnosis codes
  • Timing of combination dosing